Skip to main content

Advertisement

SpringerLink
Log in

Prediction of Short-term Survival in Patients with Advanced Nonsmall Cell Lung Cancer Following Chemotherapy Based on 2-Deoxy-2-[F-18]fluoro-d-glucose-Positron Emission Tomography: A Feasibility Study

  • Research Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Introduction

Dynamic positron emission tomography (PET) studies with 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) were performed in patients with advanced nonsmall cell lung cancer (NSCLC) who received palliative chemotherapy to evaluate the impact of full kinetic analysis and assess its value with regard to short or long survival.

Materials and Methods

The evaluation includes 42 metastatic lesions in 14 patients with NSCLC. All patients received a combined chemotherapeutic protocol consisting of vinorelbin and oxaliplatin. The survival data served as reference for the PET data. All patients were examined before onset of chemotherapy and on day 15–21 after onset of the first cycle. The following parameters were retrieved from the dynamic PET studies: standardized uptake value (SUV), fractal dimension, two-compartment model with computation of k1, k2, k3, k4 (unit: 1/min), the fractional blood volume, and the FDG-influx according to Patlak was calculated using the formula (k1 × k3) / (k2 + k3). We used a two-group classification, namely, a short- and long-term survival group based on the median survival time (193 days) as a cutoff. A support vector machines (SVM) analysis was used for classification of the two a prior defined groups.

Results

The observed survival times varied from 40 to 392 days with a median survival time of 193 days. Most kinetic parameters demonstrated only small changes mostly declining after one cycle. The change in all kinetic parameters did not correlate to the survival-based classification. The change in SUV was significant between the first and second study (p = 0.006) but without an impact on the prediction of short or long survival. SVM-based analysis revealed the highest correct classification rate (CCR) between short and long survival for the combination of SUV and influx of the first study and SUV, influx, k2, and k4 of the second study with a CCR of 95.2%.

Conclusion

The results demonstrate that a full kinetic analysis of the FDG kinetics in NSCLC is helpful for the classification into short or long survival and may be used to identify those patients who may benefit from this palliative chemotherapeutic protocol.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cancer Research UK. Incidence and mortality in the European Union. Available at: http://info.cancerresearchuk.org

  2. Socinski MA, Morris DE, Masters GA, Lilenbaum R (2003) Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 123:226S–243S

    Article  PubMed  Google Scholar 

  3. Socinski MA (2001) Chemotherapy for stage IV non-small cell lung cancer. In: Detterbeck FC, Rivera MP, Socinski MA, et al (eds) Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician. Philadelphia, PA: WB Saunders, pp 307–325

    Google Scholar 

  4. Strauss LG, Conti PS (1991) The applications of PET in clinical oncology. J Nucl Med 32:623–648

    PubMed  CAS  Google Scholar 

  5. Burger C, Buck A (1997) Requirements and implementations of a flexible kinetic modeling tool. J Nucl Med 38:1818–1823

    PubMed  CAS  Google Scholar 

  6. Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C (1998) A Java environment for medical image data analysis: initial application for brain PET quantitation. Med Inform 23:207–214

    CAS  Google Scholar 

  7. Miyazawa H, Osmont A, Petit-Taboue MC, et al (1993) Determination of 18F-fluoro-2-deoxy-d-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography. J Neurosci Methods 50:263–272

    Article  PubMed  CAS  Google Scholar 

  8. Sokoloff L, Smith CB (1983) Basic principles underlying radioisotopic methods for assay of biochemical processes in vivo. In: Greitz T, Ingvar DH, Widén L (eds) The metabolism of the human brain studied with positron emission tomography. New York: Raven, pp 123–148

    Google Scholar 

  9. Ohtake T, Kosaka N, Watanabe T, et al. (1991) Noninvasive method to obtain input function for measuring glucose utilization of thoracic and abdominal organs. J Nucl Med 32:1432–1438

    PubMed  CAS  Google Scholar 

  10. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, et al. (2003) On the fractal nature of positron emission tomography (PET) studies. World J Nucl Med 4:306–313

    Google Scholar 

  11. Moghaddam B, Yang MH (2000) Gender classification with support vector machines (abstract). In: Proceedings of the 4th IEEE International Conference on Automatic Face and Gesture Recognition, Grenoble, France, pp 306–311

  12. Dimitrakopoulou-Strauss A, Strauss LG (2006) Quantitative studies using positron emission tomography for the diagnosis and therapy planning in oncological patients. Hell J Nucl Med 9:10–21

    PubMed  Google Scholar 

  13. Weber WA, Petersen V, Schmidt B, et al. (2003) Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21:2651–2657

    Article  PubMed  CAS  Google Scholar 

  14. Couturier O, Jerusalem G, N’Guyen J-M, Histinx R (2006) Sequential Positron emission tomography using (18F)Fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res 12:6437–6443

    Article  PubMed  CAS  Google Scholar 

  15. Choi NC, Fischman AJ, Niemierko A, et al. (2002) Dose–response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54:1024–1035

    Article  PubMed  Google Scholar 

  16. Freedman NMT, Sundaram SK, Kurdziel K, et al. (2003) Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans. Eur J Nucl Med 30:46–53

    Article  Google Scholar 

  17. Keiding S, Munk OL, Schiott KM, Hansen SB (2000) Dynamic 2-(F-18)fluoro-2-deoxy-d-glucose positron emission tomography of liver tumours without blood sampling. Eur J Nucl Med 27:407–412

    Article  PubMed  CAS  Google Scholar 

  18. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, et al. (2004) Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med 45:1480–1487

    PubMed  CAS  Google Scholar 

  19. Römer W, Hanauske A-R, Ziegler S, et al. (1998) Positron emission tomography in non-Hodgkin’s lymphoma: assessment of chemotherapy with Fluorodeoxyglucose. Blood 12:4464–4471

    Google Scholar 

  20. Dimitrakopoulou-Strauss A, Strauss LG, Rudi J (2003) PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med 47:8–13

    PubMed  CAS  Google Scholar 

  21. Strauss LG, Dimitrakopoulou-Strauss A, Haberkorn U (2003) Shortened PET data acquisition protocol for the quantification of 18F-FDG kinetics. J Nucl Med 44:1933–1939

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical PET Group—Biological Imaging (E0601), Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany

    Antonia Dimitrakopoulou-Strauss, Michael Eisenhut, Leyun Pan, Uwe Haberkorn & Ludwig G. Strauss

  2. Department of Medical Oncology A, Klinikum Ludwigshafen, Ludwigshafen, Germany

    Martin Hoffmann & Raoul Bergner

  3. Department of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany

    Michael Uppenkamp

  4. Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany

    Uwe Haberkorn

Authors
  1. Antonia Dimitrakopoulou-Strauss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Hoffmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raoul Bergner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Uppenkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Eisenhut
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Leyun Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Uwe Haberkorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ludwig G. Strauss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonia Dimitrakopoulou-Strauss.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dimitrakopoulou-Strauss, A., Hoffmann, M., Bergner, R. et al. Prediction of Short-term Survival in Patients with Advanced Nonsmall Cell Lung Cancer Following Chemotherapy Based on 2-Deoxy-2-[F-18]fluoro-d-glucose-Positron Emission Tomography: A Feasibility Study. Mol Imaging Biol 9, 308–317 (2007). https://doi.org/10.1007/s11307-007-0103-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-007-0103-6

Key words

Search

Navigation